Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:160 (16 July), doi:10.1136/bmj.331.7509.160-b
| The first 150 words of the full text of this article appear below. |
EDITORThe recommendation that everyone over 50 should take aspirin ignores the issue of dose with its ratio of benefit to risk, given that a person still has at least a third of life span remaining and that older hypertensive patients are susceptible to haemorrhagic stroke.1 The debate about what is a low dose has gone on long enough, with no definite answer beyond 75 mg to over four times its multiple at 325 mg for secondary prevention of cardiovascular and cerebrovascular thrombotic disease. Aspirin across the board for primary prevention may be considered in patients with a 10% risk of coronary heart disease, and the risk-benefit balance between the number of myocardial infarctions that can be prevented and the risk of haemorrhagic stroke and gastrointestinal bleeds must be taken into account.
Bandolier has looked at randomised controlled trials in patients at low risk of cardiovascular disease and failed
Lexley M Pinto Pereira, senior lecturer
Faculty of Medical Sciences, The University of the West Indies, St Augustine, Trinidad, West Indies lexleyp@gmail.com
Read all Rapid Responses